QRxPharma

A New Pain Management Paradigm.
  • About QRxPharma
  • Technology Platforms
  • Products & Pipeline
  • Investors
  • Newsroom

Site Map

  • About QRxPharma
    • Company Profile
    • Corporate Overview Presentation
    • Milestones
    • Management
      • John W Holaday, PhD, Managing Director, CEO and CSO
      • Edward Rudnic, PhD, Chief Operating Officer
      • Chris Campbell, Chief Financial Officer
      • Janette Dixon
      • Patricia Richards, MD, PhD, Chief Medical Officer
      • Mike Schroeder, Vice President, Regulatory
    • Board of Directors
      • Peter C Farrell, PhD, ScD, AM, Non-Executive Chairman
      • John W Holaday, PhD, Managing Director, CEO and CSO
      • R Peter Campbell, Non-Executive Director
      • Gary W Pace, PhD, Director and Consultant
      • Michael A Quinn, MBA, Non-Executive Director
    • Scientific Advisory Board
      • Solomon H Snyder, MD, Chairman
      • Michael J Cousins, MD, AM
      • Lester Crawford, MD
      • Robert H Lenox, MD
      • Horace H Loh, PhD
      • Richard Payne, MD
      • Gavril W. Pasternak, MD, PhD
    • Business Strategy
    • Strategic Alliances
    • Target Markets
      • Pain Management
      • CNS Diseases & Hemostasis
  • Technology Platforms
    • Dual Opioids
    • CNS Diseases & Hemostasis Overview
  • Products & Pipeline
    • Pain Management
      • MOXDUO Immediate Release
      • MOXDUO Controlled Release
      • Q8012 Intravenous
    • Neurologic Diseases
    • Venomics
  • Investors
    • Company Profile
    • Announcements
    • Milestones
    • Corporate Overview Presentation
    • Events
    • Share Information
    • Analyst Coverage
    • Corporate Governance
    • Management
    • Board of Directors
  • Newsroom
    • Press Releases
    • Events
Technology Platform

Technology Platform

QRxPharma's platform technology, a patented fixed-ratio combination of morphine and oxycodone...

learn more
Q8003IR (tradename MOXDUO)

Q8003

QRxPharma's lead drug candidate, Q8003 (tradename MOXDUO), is intended for acute moderate to severe pain...

learn more
Product Pipeline

Products & Pipeline

QRxPharma's Dual Opioid portfolio includes three complementary products...

learn more
Investors

Investors

QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) is a commercial-stage specialty pharmaceutical company focused on...

learn more
Australia Level 1, 194 Miller St. North Sydney, NSW 2060 +61(2) 9492 8021 +61(2) 8920 0314 (fax)
United States 1430 US Highway 206 Bedminster, NJ 07921 +1 (908) 506-2900 +1 (908) 506-2918 (fax)
    • News Alerts
    • Clinical Trials
    • Site Map
    • Legal Disclaimer
©2007 – 2013 QRxPharma Ltd. All Rights Reserved.